Aclaris Therapeutics Inc. reported cash, cash equivalents, and marketable securities of $167.2 million as of September 30, 2025, down from $203.9 million at year-end 2024. The company noted decreases in revenue for the quarter and nine months ended September 30, 2025, mainly due to larger milestones achieved under the Sun Pharma license agreement and higher licensing revenue from the Eli Lilly agreement in the prior year. Research and development expenses were $13.0 million for the quarter and $36.1 million for the nine months ended September 30, 2025, compared to $6.0 million and $24.6 million in the previous year periods, driven by increased manufacturing costs, preclinical development, and clinical activities. Major business developments included positive results from the Phase 2a trial of ITK/JAK3 inhibitor ATI-2138 in atopic dermatitis, with a Phase 2 trial in another indication anticipated in the first half of 2026, and continued progress in trials for Bosakitug (ATI-045) and ATI-052. The company expects its cash reserves to fund operations into the second half of 2028.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aclaris Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-107353), on November 06, 2025, and is solely responsible for the information contained therein.
Comments